Treatment decisions based on HBV DNA

Area of Science:

• Hepatology
• Virology
• Oncology

Background:

• Chronic hepatitis B virus (HBV) infection is a leading cause of hepatocellular carcinoma (HCC) globally.
• Antiviral therapy suppresses HBV replication, reducing HCC risk and mortality, yet global treatment rates remain low (2.2% in 2019).
• Current guidelines often base treatment decisions on alanine aminotransferase (ALT) levels or liver biopsy, potentially delaying care.

Purpose of the Study:

• To review evidence linking serum HBV DNA levels to HCC risk in chronic hepatitis B (CHB) patients.
• To advocate for a revised treatment strategy based on HBV DNA levels and patient age.
• To assess the impact and cost-effectiveness of early antiviral treatment initiation.

Main Methods:

• Systematic review of existing literature on HBV DNA levels, HCC risk, and antiviral treatment outcomes.
• Analysis of the non-linear parabolic association between HBV DNA and HCC risk.
• Collating data on the potential impact and cost-effectiveness of early treatment.

Main Results:

• Serum HBV DNA levels are significantly associated with HCC risk in both treated and untreated CHB patients.
• This association follows a non-linear parabolic pattern, independent of HBeAg status or ALT levels.
• Evidence suggests early treatment initiation based on HBV DNA levels and age is beneficial.

Conclusions:

• Antiviral treatment decisions for CHB should prioritize serum HBV DNA levels and age, not solely ALT levels or liver biopsy.
• A proactive treatment approach based on viral load can significantly reduce HCC incidence.
• Early intervention is crucial for mitigating HCC risk and improving outcomes in CHB patients.